Archit Organosys (524640)
Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹49.3 |
| Market Cap | ₹101.17 Cr |
| P/E Ratio | 9.99 |
| ROCE | 10.85% |
| ROE | 12.13% |
| Dividend Yield | 1.28% |
| Profit Growth | 140.59% |
| Debt/Equity | — |
| Sales Growth | 48.43% |
| 52-Week Range | ₹34 — ₹57.8 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹33.12 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Archit Organosys looks like the kind of small-cap that Graham would at least examine: a ₹101 crore market cap against a book value of ₹33.12 per share, trading at 1.49 times book and under 10 times earnings. The trailing P/E of 9.99 and a PEG of 0.11 suggest the market is not paying up for growth. And there is growth: sales up 48.43% and profits up 140.59%. Whenever profits outpace sales by that much, I ask whether it is sustainable or simply operating leverage from a small base. The latest quarter's ₹38 crore in sales and ₹2 crore net profit show the scale; annualised, that is broadly consistent with the current valuation, but the net margin is thin.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer